Progress and challenges in TB vaccine development
This review examines the development pipeline for new TB vaccines and the challenges involved in moving vaccine candidates from preclinical research through clinical trials and eventual introduction. It discusses different vaccine platforms and candidates, clinical trial design, immune correlates of protection, regulatory requirements, funding, and the need for coordinated development programmes. It also highlights key barriers that could delay the availability of an effective TB vaccine and discusses the priorities for accelerating vaccine development
Project details
Country
Timeline
Target group
Vaccine
Type of protection of vaccine
Type of research
Partners involved
Aeras Global TB Vaccine Foundation, Institut de Pharmacologie et de Biologie Structurale, Université de Toulouse/CNRS, London School of Hygiene & Tropical Medicine, Max Planck Institute for Infection Biology, Public Health England, Sanofi Pasteur, South African Tuberculosis Vaccine Initiative (SATVI)/University of Cape Town, Tuberculosis Vaccine Initiative (TBVI), University of Oxford/Jenner Institute